ArticleNucleic acids research2025
LitSense 2.0: AI-powered biomedical information retrieval with sentence and passage level knowledge discovery.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence for Discovery in Life Sciences.Bioconjugate chemistry · 2026Review
- VectorSage: enhancing PubMed article retrieval with advanced semantic search.Bioinformatics advances · 2026Article
- Public Omics Explorer (POE): Enabling integrative semantic search across GEO omics datasets based on PubMed publications.Computational and structural biotechnology journal · 2025Article
- Retrieval-Augmented Generation in Oncology: Promises, Pitfalls, and Early Applications.AI in precision oncologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
LitSense 2.0 (https://www.ncbi.nlm.nih.gov/research/litsense2/) is an advanced biomedical search system enhanced with dense vector semantic retrieval, designed for accessing literature on sentence and paragraph levels. It provides unified access to 38 million PubMed abstracts and 6.6 million full-length articles in the PubMed Central (PMC) Open Access subset, encompassing 1.4 billion sentences and ∼300 million paragraphs, and is updated weekly. Compared to PubMed and PMC, the primary platforms for biomedical information search, LitSense offers cross-platform functionality by searching seamlessly across both PubMed and PMC and returning relevant results at a more granular level. Building on the success of the original LitSense launched in 2018, LitSense 2.0 introduces two major enhancements. The first is the addition of paragraph-level search: users can now choose to search either against sentences or against paragraphs. The second is improved retrieval accuracy via a state-of-the-art biomedical text encoder, ensuring more reliable identification of relevant results across the entire biomedical literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.